Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification

Inge van der Werf, Anna Wojtuszkiewicz, Manja Meggendorfer, Stephan Hutter, Constance Baer, Martijn Heymans, Peter J. M. Valk, Wolfgang Kern, Claudia Haferlach, Jeroen J. W. M. Janssen, Gert J. Ossenkoppele, Jacqueline Cloos, Torsten Haferlach

Blood Adv (2021) 5 (17): 3254–3265.

https://doi.org/10.1182/bloodadvances.2021004556

Published: 2021

Includes: Supplemental data

Journal Articles

Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged ≥80 years

Isabelle A. van Zeventer, Jonas B. Salzbrunn, Aniek O. de Graaf, Bert A. van der Reijden, H. Marike Boezen, Judith M. Vonk, Pim van der Harst, Jan Jacob Schuringa, Joop H. Jansen, Gerwin Huls

Blood Adv (2021) 5 (8): 2115–2122.

https://doi.org/10.1182/bloodadvances.2020004062

Published: 2021

Includes: Supplemental data

Journal Articles

A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation

Blood Adv (2021) 5 (6): 1760–1769.

https://doi.org/10.1182/bloodadvances.2020003600

Published: 2021

Includes: Supplemental data

Journal Articles

Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study

Blood Adv (2021) 5 (5): 1442–1451.

https://doi.org/10.1182/bloodadvances.2020003444

Published: 2021

Includes: Supplemental data

Journal Articles

Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes

Anthony M. Hunter, Rami S. Komrokji, Seongseok Yun, Najla Al Ali, Onyee Chan, Jinming Song, Mohammad Hussaini, Chetasi Talati, Kendra L. Sweet, Jeffrey E. Lancet, Eric Padron, Alan F. List, David A. Sallman

Blood Adv (2021) 5 (4): 1017–1028.

https://doi.org/10.1182/bloodadvances.2020003508

Published: 2021

Includes: Supplemental data

Journal Articles

Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results

Blood Adv (2020) 4 (9): 1942–1949.

https://doi.org/10.1182/bloodadvances.2019001349

Published: 2020

Includes: Supplemental data

Journal Articles

A 4-gene leukemic stem cell score can independently predict the prognosis of myelodysplastic syndrome patients

Yu-Hung Wang, Chien-Chin Lin, Chi-Yuan Yao, Chia-Lang Hsu, Hsin-An Hou, Cheng-Hong Tsai, Wen-Chien Chou, Hwei-Fang Tien

Blood Adv (2020) 4 (4): 644–654.

https://doi.org/10.1182/bloodadvances.2019001185

Published: 2020

Includes: Supplemental data

Journal Articles

Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia

Shady Adnan Awad, Matti Kankainen, Teija Ojala, Perttu Koskenvesa, Samuli Eldfors, Bishwa Ghimire, Ashwini Kumar, Soili Kytölä, Mahmoud M. Kamel, Caroline A. Heckman, Kimmo Porkka, Satu Mustjoki

Blood Adv (2020) 4 (3): 546–559.

https://doi.org/10.1182/bloodadvances.2019000943

Published: 2020

Includes: Supplemental data

Journal Articles

Ring sideroblasts in AML are associated with adverse risk characteristics and have a distinct gene expression pattern

Gerbrig Berger, Mylene Gerritsen, Guoqiang Yi, Theresia N. Koorenhof-Scheele, Leonie I. Kroeze, Marian Stevens-Kroef, Kenichi Yoshida, Yuichi Shiraishi, Eva van den Berg, Hein Schepers, Geert Huls, André B. Mulder, Seishi Ogawa, Joost H. A. Martens, Joop H. Jansen, Edo Vellenga

Blood Adv (2019) 3 (20): 3111–3122.

https://doi.org/10.1182/bloodadvances.2019000518

Published: 2019

Includes: Supplemental data

Journal Articles

Distinct clinical and biological implications of CUX1 in myeloid neoplasms

Mai Aly, Zubaidah M. Ramdzan, Yasunobu Nagata, Suresh K. Balasubramanian, Naoko Hosono, Hideki Makishima, Valeria Visconte, Teodora Kuzmanovic, Vera Adema, Aziz Nazha, Bartlomiej P. Przychodzen, Cassandra M. Kerr, Mikkael A. Sekeres, Mohamed E. Abazeed, Alain Nepveu, Jaroslaw P. Maciejewski

Blood Adv (2019) 3 (14): 2164–2178.

https://doi.org/10.1182/bloodadvances.2018028423

Published: 2019

Includes: Supplemental data

Journal Articles

A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients

Blood Adv (2019) 3 (12): 1837–1847.

https://doi.org/10.1182/bloodadvances.2018028316

Published: 2019

Includes: Supplemental data

Journal Articles

Clinicopathologic and genetic characterization of nonacute NPM1 -mutated myeloid neoplasms

Sanjay S. Patel, Caleb Ho, Ryan N. Ptashkin, Sam Sadigh, Adam Bagg, Julia T. Geyer, Mina L. Xu, Thomas Prebet, Emily F. Mason, Adam C. Seegmiller, Elizabeth A. Morgan, David P. Steensma, Eric S. Winer, Waihay J. Wong, Robert P. Hasserjian, Olga K. Weinberg

Blood Adv (2019) 3 (9): 1540–1545.

https://doi.org/10.1182/bloodadvances.2019000090

Published: 2019

Journal Articles

Clinical consequences of clonal hematopoiesis of indeterminate potential

David P. Steensma

Blood Adv (2018) 2 (22): 3404–3410.

https://doi.org/10.1182/bloodadvances.2018020222

Published: 2018

Journal Articles

Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models

Animesh Pardanani, Sahrish Shah, Francesco Mannelli, Yoseph C. Elala, Paola Guglielmelli, Terra L. Lasho, Mrinal M. Patnaik, Naseema Gangat, Rhett P. Ketterling, Kaaren K. Reichard, Curtis A. Hanson, Alessandro M. Vannucchi, Ayalew Tefferi

Blood Adv (2018) 2 (21): 2964–2972.

https://doi.org/10.1182/bloodadvances.2018026245

Published: 2018

Journal Articles

Impact of somatic and germline mutations on the outcome of systemic mastocytosis

Javier I. Muñoz-González, María Jara-Acevedo, Iván Alvarez-Twose, Jason D. Merker, Cristina Teodosio, Yanli Hou, Ana Henriques, Krishna M. Roskin, Laura Sanchez-Muñoz, Albert G. Tsai, Carolina Caldas, Almudena Matito, J. Ignacio Sánchez-Gallego, Andrea Mayado, Noelia Dasilva-Freire, Jason R. Gotlib, Luis Escribano, Alberto Orfao, Andrés C. García-Montero

Blood Adv (2018) 2 (21): 2814–2828.

https://doi.org/10.1182/bloodadvances.2018020628

Published: 2018

Includes: Supplemental data

Journal Articles

The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes

Blood Adv (2018) 2 (20): 2658–2671.

https://doi.org/10.1182/bloodadvances.2018021469

Published: 2018

Includes: Supplemental data

Journal Articles

Cell-lineage level–targeted sequencing to identify acute myeloid leukemia with myelodysplasia-related changes

Kazuaki Yokoyama, Eigo Shimizu, Nozomi Yokoyama, Sousuke Nakamura, Rika Kasajima, Miho Ogawa, Tomomi Takei, Mika Ito, Asako Kobayashi, Rui Yamaguchi, Seiya Imoto, Satoru Miyano, Arinobu Tojo

Blood Adv (2018) 2 (19): 2513–2521.

https://doi.org/10.1182/bloodadvances.2017010744

Published: 2018

Includes: Supplemental data

Journal Articles

ASXL1 impairs osteoclast formation by epigenetic regulation of NFATc1

Nidhi Rohatgi, Wei Zou, Patrick L. Collins, Jonathan R. Brestoff, Timothy H. Chen, Yousef Abu-Amer, Steven L. Teitelbaum

Blood Adv (2018) 2 (19): 2467–2477.

https://doi.org/10.1182/bloodadvances.2018018309

Published: 2018

Includes: Supplemental data

Journal Articles

Targeted next-generation sequencing in blast phase myeloproliferative neoplasms

Terra L. Lasho, Mythri Mudireddy, Christy M. Finke, Curtis A. Hanson, Rhett P. Ketterling, Natasha Szuber, Kebede H. Begna, Mrinal M. Patnaik, Naseema Gangat, Animesh Pardanani, Ayalew Tefferi

Blood Adv (2018) 2 (4): 370–380.

https://doi.org/10.1182/bloodadvances.2018015875

Published: 2018

Includes: Supplemental data

Journal Articles

Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy

Blood Adv (2017) 1 (20): 1729–1738.

https://doi.org/10.1182/bloodadvances.2017009530

Published: 2017

Includes: Supplemental data

NARROW

Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification

Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged ≥80 years

A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation

Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study

Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes

Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results

A 4-gene leukemic stem cell score can independently predict the prognosis of myelodysplastic syndrome patients

Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia

Ring sideroblasts in AML are associated with adverse risk characteristics and have a distinct gene expression pattern

Distinct clinical and biological implications of CUX1 in myeloid neoplasms

A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients

Clinicopathologic and genetic characterization of nonacute NPM1 -mutated myeloid neoplasms

Clinical consequences of clonal hematopoiesis of indeterminate potential

Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models

Impact of somatic and germline mutations on the outcome of systemic mastocytosis

The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes

Cell-lineage level–targeted sequencing to identify acute myeloid leukemia with myelodysplasia-related changes

ASXL1 impairs osteoclast formation by epigenetic regulation of NFATc1

Targeted next-generation sequencing in blast phase myeloproliferative neoplasms

Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only